Stopping an effective weight-management medicine raises a different question from starting it: what happens to the gains after treatment ends? Withdrawal studies make that question visible. They show substantial average regain after some therapies are removed, while also showing why a headline such as ‘everyone gains it all back’ is too crude.
The evidence is useful for planning long-term care. It is not a reason to shame someone who stops because of symptoms, pregnancy, access or preference, and it does not identify a safe personal taper. Decisions about continuation or withdrawal should be made with the care team and with the original treatment goal in view.
STEP 1 followed participants after treatment ended
In the STEP 1 extension, a subset of adults without diabetes was followed for a year after 68 weeks of semaglutide treatment or placebo. The structured lifestyle intervention also ended. Participants previously receiving semaglutide regained an average of 11.6 percentage points of starting weight by week 120, leaving average weight 5.6% below the original baseline.
The researchers described this as regaining about two-thirds of the prior weight loss. That is a proportion of the earlier loss, not a statement that weight rose by two-thirds of starting body weight. Cardiometabolic improvements tended back toward baseline for many measures. Individual experiences varied, and the extension was not the full original randomized trial population.
Two details matter for interpretation. First, this was a selected extension cohort rather than a new randomized comparison of every possible maintenance strategy. Second, medication and structured lifestyle support ended together. The result should not be described as a clean experiment isolating medication withdrawal while all other support stayed identical. It still provides important follow-up evidence, but its design limits the causal question it answers.
SURMOUNT-4 directly randomized continuation versus withdrawal
SURMOUNT-4 used a different design. Adults with obesity or overweight without diabetes first received tirzepatide during a 36-week open-label period. Participants who completed that lead-in and met the trial’s requirements were then randomized to continue tirzepatide or switch to placebo for another 52 weeks.
Among randomized participants, the initial mean weight reduction was 20.9%. From week 36 to week 88, mean weight changed by minus 5.5% in the continuation group and plus 14.0% in the placebo-switch group. These later percentages use weight at randomization as the reference. They should not simply be added to or subtracted from the first percentage, which uses a different baseline.
This randomized withdrawal stage provides stronger evidence for the effect of continuing the studied regimen versus removing it in this selected population. It does not describe all people who first consider treatment, because individuals who could not complete the lead-in are not represented in the same way. Selection after initial treatment is important when discussing tolerability and real-world continuation.
What the two studies agree on
Both studies show that initial weight reduction does not automatically remain unchanged after effective treatment is removed. Continued support and reassessment matter. The studies support treating maintenance as an active phase of care rather than assuming the weight-loss phase has permanently solved the problem.
They do not establish one unavoidable trajectory for every person. Some participants retained more loss than others, follow-up was limited, and the available studies tested particular regimens and settings. The evidence does not prove that every person requires the same product forever or that alternative maintenance approaches can never work.
NIDDK describes obesity medicines within long-term management, where benefits and adverse effects should be reviewed over time. That framework is compatible with withdrawal findings: continuing an effective, tolerable treatment can be reasonable, while changed circumstances can still justify reconsideration. A chronic condition does not make every individual treatment decision permanent.
Regain is not evidence of personal failure
A trial average cannot measure how hard someone tried after stopping. Regain after withdrawal should not be converted into a moral judgment about eating, motivation or willpower. The important observation is that the treatment environment changed and weight often changed with it.
This also means that stopping does not erase every benefit instantly. In STEP 1’s extension, average weight remained below the original baseline at the final observed point. But retaining some loss is different from retaining all earlier improvements. A care review should consider weight, relevant health measures, function and symptoms separately.
Our plateau guide explains why a stable weight while on treatment is not automatically treatment failure. Likewise, maintenance can be a benefit even when weight is no longer falling. Removing a treatment because the scale has stopped decreasing may therefore need a discussion of what is being maintained.
The trials do not supply a personal taper
Neither headline result tells a reader how to reduce doses, extend intervals or convert to another product. A withdrawal trial’s switch to placebo is a research design, not a general discontinuation prescription. The appropriate plan depends on the medicine, intended indication, other treatments and reason for stopping.
A person using treatment for diabetes, cardiovascular risk or another indication needs that goal reviewed too. Stopping a product used for more than weight may affect a wider care plan. The relevant specialist and prescriber should coordinate monitoring and any replacement treatment. Do not assume the scale is the only outcome needing attention.
Product labels also contain specific instructions for pregnancy, adverse effects and interruptions. Pregnancy planning is one situation where stopping may be necessary even after a good response. The decision should preserve safe care rather than force a person to choose between pregnancy plans and unsupported self-management.
Plan for foreseeable interruptions
Before starting, ask what happens if coverage ends, the pharmacy cannot supply the product or symptoms become difficult. These are common types of uncertainty, but their consequences should be managed prospectively. Contact the team before an extended gap when possible.
A maintenance discussion can include follow-up timing, relevant health measures, support with food and activity, and when to reassess a changing weight trajectory. These are care-process questions rather than a guaranteed anti-regain formula. Support should remain available even if the medicine cannot continue.
Ask which instructions apply if restarting becomes appropriate. A previous maintenance dose is not automatically the right place to resume after a gap. Our escalation guide explains why product-specific restart advice matters.
Use withdrawal evidence to improve the plan
The strongest takeaway is that maintenance needs planning before withdrawal, rather than judgment after regain. The studies make the possible consequences visible and create better questions: what benefit is currently being maintained, why might treatment stop, and how will the next phase be supported?
An informed decision can still be to stop, continue or reassess another approach. What the evidence discourages is assuming that an earlier average loss guarantees permanent stability without ongoing care. A clear follow-up plan is useful whichever decision the care team and patient make together.
